Skip to main content

INJURY REPAIR

TENDON & SOFT TISSUE HEALING PROTOCOL

3-Phase Recovery

12 week structured protocol

WEEKS 1-2
Activation
Restart healing, reduce inflammation
WEEKS 3-6
Remodeling
Build collagen, restore tissue
WEEKS 7-10+
Integration
Consolidate, return to function
The Systemic Healer

BPC-157

Restores angiogenesis and perfusion. Activates VEGFR2-Akt-eNOS signaling, accelerates fibroblast migration and upregulates Type I/III collagen.

Cell Migration Orchestrator

TB-500

Regulates actin dynamics for efficient cell migration and proper spatial organization. Reduces adhesions between tissue planes.

Collagen Architecture Optimization

GHK-Cu

Regulates matrix metalloproteinases to break down disorganized collagen while upregulating organized synthesis. Orchestrates transition from reactive scar tissue to functional matrix.

Anti-Inflammatory Master Switch

KPV

Directly blocks NF-κB—the master transcription factor orchestrating inflammatory gene expression—with precision and without systemic immunosuppression.

The Power Supply

NAD+

Powers cellular energy systems driving all tissue regeneration. Fuels metabolic processes behind collagen production, DNA repair, and cellular turnover—giving cells the energy reserves needed to execute healing.

STALLED HEALING

Angiogenesis stops, fibroblasts go dormant—tissue can't get nutrients or healing signals

CHRONIC INFLAMMATION

Overactive immune response creates heat, swelling, pain—blocks tissue from rebuilding

POOR TISSUE QUALITY

Disorganized collagen forms scar tissue—weak, inflexible, prone to re-injury

LIMITED CELL MIGRATION

Cells can't move to injury site, tissue planes stick together, mobility restricted

BPC-157

Restarts perfusion and cellular activation through VEGFR2-Akt-eNOS signaling

KPV

Calms inflammation without suppressing repair by directly blocking NF-κB

GHK-CU

Optimizes collagen architecture by regulating matrix metalloproteinases

TB-500

Enables cell migration and tissue organization by regulating actin dynamics

  • Active malignancy or proliferative retinopathy → avoid BPC-157 & TB-500 (angiogenic)
  • Wilson's disease → avoid GHK-Cu
  • Pregnancy / breastfeeding → insufficient safety data